Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Oncology researchers reviewing head and neck cancer imaging data, reflecting the clinical focus of Inhibrx Biosciences’ INBRX-106 HexAgon study update in first-line HNSCC and the broader immuno-oncology race to improve pembrolizumab-based treatment strategies.
Pharma & Biotech

Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures

OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Representative image: A clinician discusses neuromuscular treatment options with an adult patient as Argenx SE’s expanded Vyvgart approval broadens the FDA label across all adult generalized myasthenia gravis serotypes, strengthening interest in targeted FcRn therapies for autoimmune neurology.
Pharma & Biotech

Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis

Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.

Read More
Representative image: ALX Oncology’s evorpacept update highlights how CD47-high biomarker data and HER2-positive metastatic breast cancer trial design could shape the next phase of oncology drug development.
Pharma & Biotech

Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study

ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.

Read More
Representative image: Moderna’s early hantavirus vaccine work highlights how mRNA vaccine platforms could support rare-virus preparedness as outbreak-driven concerns renew focus on infectious disease innovation.
Pharma & Biotech

Can Moderna turn hantavirus urgency into a credible rare-virus vaccine strategy?

Moderna surged on hantavirus hopes. The real test is whether rare-virus urgency can become a viable mRNA vaccine pathway.

Read More
Representative image of a modern medical cannabis dispensary in coastal Florida, highlighting Curaleaf Holdings, Inc.’s expanding retail footprint as the company adds new locations in Jacksonville Beach and Fernandina Beach.
Pharma & Biotech

Curaleaf adds Jacksonville Beach and Fernandina Beach dispensaries to deepen Florida reach

Curaleaf is adding Florida stores as cannabis investors demand proof of profitable scale. The next test is store productivity, not footprint.

Read More
Representative image: Advanced AAV gene therapy manufacturing platforms such as AAVnerGene’s AAVone 2.1 are drawing attention as biotech developers look to improve vector productivity, full-capsid yield, and scalable production economics.
Pharma & Biotech

Why AAVnerGene’s AAVone 2.1 could matter for next-generation gene therapy manufacturing

AAV gene therapy needs better economics. AAVnerGene’s AAVone 2.1 tests whether single-plasmid production can ease the scale-up squeeze.

Read More
Representative image of a pediatric oncology consultation as Servier and Day One advance FIREFLY-2, a pivotal trial testing OJEMDA as a potential front-line treatment for BRAF-altered pediatric low-grade glioma.
Pharma & Biotech

Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment

OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.

Read More
Representative image: Basata’s $21 million Series A highlights how AI agents could help specialty healthcare practices move from fax-based referrals and manual scheduling to faster digital intake, patient follow-up and administrative workflow automation.
Pharma & Biotech

Basata raises $21m as investors target the hidden cost of healthcare administration

Healthcare AI is moving from diagnosis to operations. Basata’s $21M raise tests whether referrals and scheduling can finally escape fax-era friction.

Read More
Representative image: A biotech researcher reviews oncology trial data and molecular analysis as Enliven Therapeutics advances ELVN-001 toward a pivotal chronic myeloid leukemia study, highlighting the clinical and investor stakes behind its Q1 2026 update.
Pharma & Biotech

Enliven Therapeutics moves closer to Phase 3 as ELVN-001 faces its real test

ELVN-001 has early CML promise and a long cash runway. Phase 3 execution now decides whether Enliven Therapeutics can justify the hype.

Read More